Nexstim Plc: Directed Share Issue without consideration


Company announcement, inside information, Helsinki, 7 April 2021 at 8.15 PM (EEST)

Nexstim Plc: Directed Share Issue without consideration

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces with reference to the company announcements dated 8 March 2021 regarding a subscription rights issue (“Share Issue”)  and approval of a EU growth prospectus (“Prospectus”) as well as the subscription underwriting commitments provided for the Company in connection with such Share Issue.

Company’s major shareholders, Ossi Haapaniemi, Kyösti Kakkonen and Leena Niemistö, jointly with related-party companies / book entry accounts controlled by each, as well as the certain members of the company’s Board of Directors and management team, committed on certain terms and conditions, to subscribing for in aggregate approximately 47.83% of the offer shares (“Offer Shares”) in the above-mentioned Share Issue as follows:

Commitment provided bySubscription commitment (in EUR)Subscription commitment (Offer Shares)% of all Offer Shares
Ossi Haapaniemi with his related-party companies722,608.6524,086,95510.96
Kyösti Kakkonen with his related-party companies and book-entry accounts controlled1,200,000.0040,000,00018.20
Leena Niemistö representing Kaikarhenni Oy1,100,000.0036,666,66716.68
Member of Board of Directors Martin Forss40,000.001,333,3340.61
Member of Board of Directors Tomas Holmberg5,000.00166,6670.08
Managing director Mikko Karvinen 30,000.001,000,0000.45
Management team member Hanna Kotola 25,000.00833,3340.38
Management team member Joonas Juokslahti 5,000.00166,6670.08
Management team member Gustaf Järnefelt14,000.00466,6670.21
Management team member Jarmo Laine6,321.06210,7020.10
Management team member Henri Hannula6,000.00200,0000.09
In total3,153,929.71105 130 99347.83

In accordance with the terms of the subscription underwriting commitments, the Company shall give to those parties who have provided subscription underwriting commitments an underwriting commitment fee corresponding to 4% of the aggregate amount of the subscription underwriting commitment by issuing up to 4,205,236 new shares of the Company (“New Shares”) to those parties without consideration. The total amount of the underwriting commitment fee payable to each such party in shares of the Company is equal to the amount of the fee based on the above-mentioned respective subscription underwriting commitment divided by the subscription price of the Share Issue i.e. EUR 0,03. The Company is entitled to reimburse the possible remainder of the underwriting commitment fee in cash to the commitment provider.

Pursuant to the share issue authorization of 5,000,000 shares provided for the Board of Directors by the extraordinary general meeting on 1 March 2021 and based on the above-mentioned subscription underwriting commitments, the Board of Directors of the Company has today decided to issue, in a directed share issue, in total 4,205,236 New Shares of the Company without consideration in accordance with section 17 chapter 9 of the Finnish Limited Liability Companies Act as follows:

Shares received byShares (number)
Haapaniemi Ossi Antero 495,556
Haapaniemi Ossi Antero249,988
Haapaniemi Ossi / Kalksten Finance Oy63,471
Haapaniemi Ossi / Kalksten Properties Koy154,462
Kyösti Kakkonen / Joensuun Kauppa ja Kone Oy933,333
Kyösti Kakkonen / K22 Finance Oy266,666
Kyösti Kakkonen / Kakkonen Kari Heikki Ilmari266,666
Kyösti Kakkonen / Bocap Investment Oy133,333
Leena Niemistö / Kaikarhenni Oy1,466,666
Martin Forss53,333
Tomas Holmberg6,666
Mikko Karvinen40,000
Hanna Kotola33,333
Joonas Juokslahti6,666
Gustaf Järnefelt18,666
Jarmo Laine8,428
Henri Hannula8,000

As the subscription underwriting commitments have been material to the successful outcome of the Share Issue, and taking into account the particularly material significance of the Share Issue to financing of the company’s business and for overall continuation of its operations, the Board of Directors considers that there is a particularly weighty financial reason for the directed share issue without consideration both from the point of view of the Company as well as the interests of all its shareholders.

The New Shares issued represent approximately 0.6 per cent of all the shares in the Company after the registration, including also the Offer Shares subscribed in the Company's subscription rights issue which are expected to be registered within the Trade Register on 12 April 2021.

The New Shares are expected to be registered with the Finnish Trade Register on or about 12 April 2021 and are expected to be listed on First North Finland on or about 13 April 2021 and First North Sweden on or about 14 April 2021. After the New Shares have been registered with the Finnish Trade Register (considering also Offer Shares subscribed in the Company's subscription rights issue which are also expected to be registered with the Trade Register on 12 April 2021), the total number of registered shares in the Company will be 663 639 370.


Leena Niemistö, Chair of the Board of Directors

Further information is available on the website, or by contacting:

Leena Niemistö, Chair
+358 9 2727 170

Erik Penser Bank AB (Certified Adviser)                        
 +46 8 463 83 00

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 202110.4.2021 14:30:00 CEST | Press release

Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed EOS-448 showed preliminary signs of clinical activity as a monotherapy, including a partial response in one pembrolizumab-resistant melanoma patient, and stable disease in multiple patients EOS-448 reduced TIGIT+ suppressive T regulatory cells and CD8 T cells considered to be exhausted at all tested doses, indicating engagement of FcγR, an essential component in many immune system effector functions Company to advance EOS-448 into combination trials with pembrolizumab and other novel agents in both checkpoint-naïve and resistant patients Company to host conference call on Monday, April 12th at 8:00 a.m. EDT to discuss results CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company

Notice to Annual General Meeting 20219.4.2021 21:45:00 CEST | Press release

Shareholders in MICRO SYSTEMATION AB (publ) are hereby given notice to attend the Annual General Meeting (AGM) on Tuesday, 11 May 2021, at 18.00 at MSAB’s premises at Hornsbruksgatan 28 in Stockholm. Registration for the AGM will commence at 17:15. Because of COVID-19 (the Corona virus), MSAB is prioritising health and safety and has thus decided to hold the AGM on Company premises, Hornsbruksgatan 28 in Stockholm, and keep the meeting as brief as possible and to provide the opportunity for shareholders to also vote by post. No food will be served. The demonstration and display of the Company’s products normally given in conjunction with the AGM are cancelled. Questions for Company management can be sent to Against the backdrop of recommendations issued by Swedish authorities, all shareholders are encouraged to consider utilising the possibility of voting by mail via a form which will be available on the Company’s website ( rather than physically a

Kallelse till årsstämma 20219.4.2021 21:45:00 CEST | Pressemelding

Aktieägare i MICRO SYSTEMATION AB (publ) kallas härmed till årsstämma tisdagen den 11 maj 2021 kl. 18.00 i MSABs lokaler på Hornsbruksgatan 28 i Stockholm. Inregistrering till årsstämman börjar klockan 17:15. Med anledning av COVID-19 (Corona-viruset) har MSAB, för att sätta hälsa och säkerhet i första rummet, beslutat att hålla stämman i bolagets lokaler, Hornsbruksgatan 28 i Stockholm och att korta stämman så långt som möjligt, samt ge aktieägarna möjlighet att före stämman utöva sin rösträtt per post. Någon servering kommer inte att förekomma. Demonstration och visning av bolagets produkter som normalt görs i samband med stämman är inställd. Frågor till bolagsledningen kan skickas till . Mot bakgrund av myndigheternas föreskrifter uppmanas alla aktieägare att överväga att istället för att närvara fysiskt vid stämman utnyttja möjligheten att poströsta via formulär på bolagets hemsida RÄTT TILL DELTAGANDE Aktieägare i Micro Systemation AB (publ),

RomReal: Mandatory notification of insider trade - Chairman and CEO of RomReal Kjetil Gronskag9.4.2021 18:43:18 CEST | Press release

Kjetil Gronskag, Chairman and CEO of RomReal Ltd has today 09 April 2021, purchased 9 shares of RomReal at NOK 1.75 per share in RomReal Ltd. Following this trade, Kjetil Gronskag controls privately and through holding companies 4,475,739 shares in RomReal Ltd. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act


Bid procedure, 2021-04-14BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VATTENFALL AB: XS0328561286, 2022-11-01 STANGASTADEN AB: SE0012193860, 2024-09-27 HEBA FASTIGHETS AB: SE0013882875, 2026-03-02 SWEDISH MATCH AB: XS1619638528, 2022-05-30 SWEDISH MATCH AB: XS2306815114, 2026-02-24 SVENSKA CELLULOSA AB SCA: SE0013882560, 2025-09-23 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2021-03-14Bid date2021-04-14Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS0328561286: 30 mln SEK +/-30 mln SEK SE0012193860: 30 mln SEK +/-30 mln SEK SE0013882875: 30 mln SEK +/-30 mln SEK XS1619638528: 30 mln SEK +/-30 mln SEK XS2306815114: 30 mln SEK +/-30 mln SEK SE0013882560: 30 mln SEK +/-30 mln SEK Highest permi


Bid procedure, 2021-04-14CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-10-14 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-04-02 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to date2021-04-14Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s


Bid procedure, 2021-04-16BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 KINGDOM OF SWEDEN: REGS, XS2226974504, 2030-09-09 Bid date2021-04-16Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 750 mln SEK +/-400 mln SEK 1053: 500 mln SEK +/-250 mln SEK REGS: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 750 mln SEK per bid 1053: 500 mln SEK per bid REGS: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-04-20Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-04-09 This is a translation of the special terms and conditions published on In the case of any inconsistency between the English translation